Hormonal
Obesity increases the risk of nephrolithiasis (kidney stones) through mechanisms including lower urine pH, increased urinary oxalate, uric acid, and sodium excretion, and insulin resistance-induced acidic urine.
If you are overweight, you are at higher risk for kidney stones because your body's metabolism changes how your urine is made. Insulin resistance makes your urine more acidic and increases the amount of stone-forming minerals like oxalate and uric acid you excrete. Managing your weight and insulin sensitivity is key to preventing stones, not just avoiding specific stone-causing foods.
Obesity is associated with a number of risk factors contributing to the higher incidence and prevalence of nephrolithiasis. Higher body weight is associated with lower urine pH and increased urinary oxalate, uric acid, sodium and phosphate excretion... The insulin resistance characteristic of obesity may also predispose to nephrolithiasis through its impact on tubular Na-H exchanger and ammoniagenesis, and the promotion of an acidic milieu.
Why this rating
Supported by population-based studies linking BMI and weight gain to stone incidence.
Source
Obesity and kidney disease: hidden consequences of the epidemic
Csaba P. Kövesdy et al. · Revista médica de Chile · 2017
DOI 10.4067/s0034-98872017000300001
More from this paper
- Obesity is a significant risk factor for kidney cancer, with a 5 kg/m2 higher BMI associated with a 25% higher risk of kidney cancers, and 10-26% of all kidney cancers attributable to excess weight.Strong
- High body mass index (BMI) and obesity are strong, independent risk factors for the development and progression of chronic kidney disease (CKD), end-stage renal disease (ESRD), and obesity-related glomerulopathy (ORG).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →